Trident Lifeline issued a corrigendum to its Extra-Ordinary General Meeting (EGM) notice on October 16, 2026, following stock exchange instructions regarding its proposed preferential allotment.

The company had previously announced plans to issue 12,22,200 equity shares and 5,00,400 warrants under SEBI (ICDR) Regulations, 2018. The board meeting held on October 16, 2026, authorized changes to the explanatory statement to address regulatory queries and ensure compliance with listing obligations.

Revised Fund Utilization Plan

The corrigendum specifies the deployment of proceeds from the preferential issue of equity shares. The total proposed amount for this tranche is ₹4,113.93 lakh, to be utilized within 24 months from the receipt of funds.

A separate table in the notice outlines a second tranche or warrant-related allocation totaling ₹1,684.35 lakh, with similar distribution across working capital, subsidiary investments, and general corporate purposes.

Updated Allottee Details

The board approved changes to the Ultimate Beneficial Owner (UBO) details for specific allottees in Item No. 2 of the EGM notice. These updates clarify the identity of beneficiaries behind certain corporate entities receiving shares.

Regulatory Compliance and Next Steps

The company also provided links to compliance certificates issued by the Practising Company Secretary (PCS) for both Item No. 2 and Item No. 3 of the EGM agenda. This step ensures transparency in the procedural aspects of the preferential issue.

The board concluded that these amendments were necessary to settle questions arising from stock exchange instructions. The revised draft of the corrigendum was approved during the meeting, which commenced at 1:30 pm and concluded at 1:45 pm. Shareholders will now vote on the amended special resolution and explanatory statement.

Trident Lifeline Limited disclosed that its shareholding in subsidiary Trident Mediquip Limited has decreased to 58.23% following a private placement of equity shares to other shareholders. The reduction from the previous holding of 59.67% reflects a dilution of promoter interest in the medical device unit.

The transaction, executed on October 15, 2026, involves the allotment of shares by Trident Mediquip Limited (TML) to entities including directors and relatives of the parent company's promoters. Despite the reduced stake, Trident Lifeline retains majority control over the Surat-based subsidiary. The filing confirms the transaction was undertaken on an arm's length basis, classifying it as a related party transaction under SEBI regulations.

Subsidiary financial performance

Trident Mediquip Limited operates in the medical device industry and has shown consistent revenue growth over the last three fiscal years. The subsidiary's turnover rose from ₹20.58 crore in FY24 to ₹27.31 crore in FY26. The capital structure shows an authorized share capital of ₹11 crore and paid-up share capital of ₹10.25 crore.

Related party details and governance

The private placement involved allotments to individuals with existing ties to the parent company. Mr. Amit Bhupendra Halvawala and Mr. Chetan Chandrakant Jariwala, identified as relatives of director Rupaben Jariwala, along with Mr. Hardik Jigishkumar Desai, are part of the promoter group or board of Trident Lifeline. These individuals hold interests in Trident Mediquip, reinforcing the related-party nature of the equity infusion.

No governmental or regulatory approvals were required for this specific internal restructuring of shareholding patterns. The company stated that the primary objective was to facilitate the allotment of shares to other shareholders, thereby adjusting the ownership percentage while maintaining operational consolidation.

What the numbers show

While Trident Lifeline's stake in Trident Mediquip declined by 1.44 percentage points, the subsidiary's revenue expanded significantly during the same period. Turnover grew from ₹21.29 crore in FY25 to ₹27.31 crore in FY26, representing a substantial year-on-year increase. This divergence suggests that the dilution in ownership percentage occurred alongside strong top-line growth for the subsidiary, potentially indicating value accretion for remaining shareholders despite the lower equity share.